Cost–Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China-Reference-Cited by-同舟云学术

Cost–Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China

Published:2022-12-26 Issue:3 Volume:40 Page:1087-1103
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Ming Jian^ORCID,Wu Yuxia,Han Rong,Xu Xing,Waldeck Reg,Hu Shanlian

Funder

Bayer Healthcare Company Ltd

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-022-02389-7.pdf

Reference42 articles.

1. WHO. Estimated crude incidence/mortality rates in 2020 prostate, males, all ages. Global Cancer Observatory website. Retrieved 2021, from https://gco.iarc.fr/today/home.

2. Wang F, Wang C, Xia H, et al. Burden of prostate cancer in China, 1990–2019: findings from the 2019 global burden of disease study. Front Endocrinol (Lausanne). 2022;13: 853623. https://doi.org/10.3389/fendo.2022.853623.

3. Wong MC, Goggins WB, Wang HH, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol. 2016;70(5):862–74. https://doi.org/10.1016/j.eururo.2016.05.043.

4. Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol. 2018;25(6):524–31. https://doi.org/10.1111/iju.13593.

5. Gu XY, Zhang RS, et al. Analysis on the trend of prostate cancer incidence and age change in cancer registration areas of China, 2000 to 2014. Chin J Prev Med. 2018;52(6):586–92. https://doi.org/10.3760/cma.j.issn.0253-9624.2018.06.006.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with highvolume, metastatic, hormone-sensitive prostate cancer;Frontiers in Pharmacology;2024-01-09

2. Development and validation of a novel nomogram predicting clinically significant prostate cancer in biopsy‐naive men based on multi‐institutional analysis;Cancer Medicine;2023-11-28